A trial looking at cobimetinib and paclitaxel for triple negative breast cancer

This trial is looking at a new drug called cobimetinib and a chemotherapy drug called paclitaxel for triple negative breast cancer. This means the breast cancer doesn’t have receptors for the hormones progesterone and oestrogen, or for the protein HER2. The trial is for people whose cancer has grown into surrounding tissue (is locally advanced) or has spread to another part of their body.